Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure

被引：0
|
作者：
Painchaud, CA
Ghazzi, MM
Selaru, P
Bichet, DG
Chartier, KK
Udelson, JE
机构：
[1] Parke Davis Pharmaceut Res, Ann Arbor, MI USA
[2] Hosp Sacre Coeur Montreal, Montreal, PQ, Canada
[3] New England Med Ctr, Boston, MA 02111 USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2603
引用
收藏
页码：535 / 535
页数：1
相关论文
共 50 条
  • [21] Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
    Greenberg, Arthur
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (06) : 904 - 907
  • [22] Efficacy and Safety of the Vasopressin V1A/V2-Receptor Antagonist Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot Study
    Goldsmith, Steven R.
    Elkayam, Uri
    Haught, W. Herbert
    Barve, Abhijit
    He, Weizhong
    JOURNAL OF CARDIAC FAILURE, 2008, 14 (08) : 641 - 647
  • [23] Chronic vasopressin V1A but not V2 receptor antagonism prevents heart failure in chronically infarcted rats
    Van Kerckhoven, R
    Lankhuizen, I
    van Veghel, R
    Saxena, PR
    Schoemaker, RG
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 449 (1-2) : 135 - 141
  • [24] Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?
    Mondritzki, T.
    Pook, E.
    Wasnaire, P.
    Schmeck, C.
    Kolkhof, P.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1317 - 1317
  • [25] Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure
    Smith, WB
    Russell, S
    Ghali, JK
    Painchaud, CA
    Ghazzi, MM
    Konstam, MA
    Udelson, JE
    Selaru, P
    EUROPEAN HEART JOURNAL, 2001, 22 : 541 - 541
  • [26] Efficacy and safety of oral conivaptan:: A V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
    Ghali, Jalal K.
    Koren, Michael J.
    Taylor, James R.
    Brooks-Asplund, Esther
    Fan, Kaisheng
    Long, Walker A.
    Smith, Neila
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06): : 2145 - 2152
  • [27] Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?
    Goldsmith, Steven R.
    Udelson, James E.
    Gheorghiade, Mihai
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (02) : 112 - 114
  • [28] Pharmacological characterization of RWJ-676070, a dual vasopressin V1A/V2 receptor antagonist
    Gunnet, Joseph W.
    Wines, Pamela
    Xiang, Min
    Rybczynski, Philip
    Andrade-Gordon, Patricia
    de Garavilla, Lawrence
    Parry, Tom J.
    Cheung, Wai-man
    Minor, Lisa
    Demarest, Keith T.
    Maryanoff, Bruce E.
    Damiano, Bruce P.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 590 (1-3) : 333 - 342
  • [29] Pharmacotherapy for hyponatremia in heart failure:: Effects of a new dual V1A/V2 vasopressin antagonist YM087
    Abraham, WT
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    McCord, J
    Rydzinski, S
    Nelson, CB
    Bakker-Arkema, RG
    CIRCULATION, 1999, 100 (18) : 299 - 299
  • [30] Neurohormonal antagonism in heart failure;: beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition
    Naitoh, M
    Risvanis, J
    Balding, LC
    Johnston, CI
    Burrell, LM
    CARDIOVASCULAR RESEARCH, 2002, 54 (01) : 51 - 57
12345